

# **Evaluation of targeted oxidative stress induced by oxygen-ozone gas mixtures *in vitro* after ischemic induction**

## **Effects of oxygen-ozone *in vitro* after ischemic induction**

Jessica Rodrigues Orlandin<sup>1,2\*</sup>, Sarah Ingrid Pinto Santos<sup>1</sup>, Luciana Cristina Machado<sup>1</sup>, Paulo Fantinato Neto<sup>1</sup>, Fabiana Fernandes Bressan<sup>1</sup>, Naira Caroline Godoy Pieri<sup>1</sup>, Kaiana Recchia<sup>1</sup>, Meline de Paula Coutinho<sup>1</sup>, Priscilla Avelino Ferreira Pinto<sup>1</sup>, Annalisa Santucci<sup>2</sup>, Valter Travagli<sup>2</sup>, Carlos Eduardo Ambrosio<sup>1</sup>

<sup>1</sup> Veterinary Medicine Department, Faculty of Animal Science & Food Engineering, University of San Paulo, Pirassununga, San Paulo, Brazil.

<sup>2</sup> Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Siena, Tuscany, Italy

\*Corresponding author:

E-mail: [jessica.vet@usp.br](mailto:jessica.vet@usp.br)

## ABSTRACT

Encephalic vascular accident, or stroke, is the most common pathology of the central nervous system in humans. It is the second leading cause of death, as well as physical and cognitive disabilities, in developing countries. It is a vascular disorder that may present in an ischemic (more common) or hemorrhagic form. Ozone is a gas capable of oxidizing double bonds of organic molecules, thereby producing lipoperoxides and aldehydes. Stimulation of the immune and antioxidant system, and improvement in tissue vascularization and oxygenation, are few among several effects exerted by ozone. Ozone therapy has previously been shown to be effective in neuromodulation, neuroprotection, and nerve regeneration. The present study aimed to evaluate the effect of targeted mild ozone after inducing cerebral ischemia *in vitro*. The experiment was divided into two steps; in the first step, neuroblastoma lineage cells (SH-SY5Y) were subjected to 24 hours of hypoxia in an incubator culture chamber. Treatment with different concentrations of ozone (2–10 µg/mL), followed by an 2,5-diphenyl-2H-tetrazolium bromide assay, indicated a possible neuroregenerative effect at low concentrations. The same protocol was applied to canine amniotic membrane stem cells that were evaluated via colorimetric assay spectrophotometry, fluorescence microscopy, and flow cytometry. The metabolic conditions and cellular regeneration in cells at low ozone concentrations (3–8 µg/mL) correlated with lower levels of apoptosis and oxidative stress compared to cells not subjected to hypoxia. High concentrations of ozone (18–30 µg/mL) promoted an increase in rate of apoptosis and cell death. Therefore, we developed a novel protocol that mimics ozone therapy for ischemic stroke, using ozonized culture medium after hypoxia induction. Although more studies are needed to open new avenues for translational medicine, we conclude that ozone has a dose-dependent hormetic effect and can reverse the effect of ischemia *in vitro* at low concentrations.

**Keywords:** *ischemic stroke, hypoxia, ozone therapy, cell ozonation.*

## 49 INTRODUCTION

50

51 A stroke is a neurological deficit caused by an altered brain circulation. This  
52 term includes injuries caused by hemodynamic and clotting disorders in arteries or  
53 veins (1) and is the most common pathology of the central nervous system. Recent  
54 studies indicate that stroke has become the second leading cause of death due to  
55 physical and cognitive disabilities in developed countries (2,3). According to a 2021  
56 report from the American Heart Association, ischemic strokes account for 87% of  
57 stroke cases (4). The main risk factors for stroke are hypertension, obesity, sedentary  
58 lifestyle, stress, high cholesterol, and smoking (5).

59 In ischemic stroke, interrupting cellular oxidative metabolism reduces  
60 phosphate and glucose production, releasing neurotransmitters and increasing  
61 calcium and sodium levels. These factors lead to a reduction in neuronal metabolism  
62 and mitochondrial function; energy insufficiency; formation of arachidonic acid,  
63 prostaglandin, and leukotrienes; vasoconstriction; platelet aggregation; and poor  
64 microvasculature (6,7).

65 Ozone is a gas composed of three oxygen atoms, performing a specialized  
66 function of oxidizing double bonds of organic molecules. It is a powerful oxidant that  
67 immediately reacts with hydrophilic antioxidants in plasma, such as uric acid,  
68 ascorbic acid, and albumin, producing lipoperoxides and aldehydes. Ozone exhibits a  
69 hormetic effect; it can peroxidize the erythrocyte membrane and induce a change in  
70 its negative charge, causing minimal oxidative stress. Moreover, it improves  
71 circulation and oxygen delivery in ischemic tissues, enhances cell metabolism,  
72 modulates antioxidant enzymes, induces a slight activation of the immune system,  
73 and increases the release of growth factors. Ozone also induces platelet  
74 degranulation, stimulates the neuroendocrine system, activates neuroprotective  
75 strategies, protects against apoptosis induced via oxidative stress, and increases  
76 gene repair activity. When administered in adequate concentration, no side effects  
77 are observed (8–13).

78 Previous studies indicate that ozone therapy can be effective in  
79 neuromodulation, neuroprotection, and nerve regeneration (14–21). However, very  
80 few studies use the technique for stroke or other low cerebral perfusion syndromes  
81 (14,21,22).

It is worth noting that most studies use ozone as a preconditioning strategy before inducing hypoxia. This approach is not feasible since patients affected by this type of illness seek treatment only after the onset of symptoms and not as prevention. Our pioneering research efforts utilize ozone after hypoxia, with cells still in culture, without resuspending them for ozone treatment.

The present study aimed to evaluate the *in vitro* effects of mild oxidative stress caused by ozone after induction of cerebral ischemia, mimicking an ischemic stroke. Ozone therapy, when applied in adequate concentrations, improves oxygenation levels and cell metabolism, promoting cell regeneration. The experiment was conducted in two phases, using neuroblastoma cells and amniotic membrane stem cells.

Neuroblastoma lineage cells (SH-SY5Y) were cultured *in vitro*, subjected to hypoxia in an incubator culture chamber, and then treated with different ozone concentrations (2–30 µg/mL). As expected, 2,5-diphenyl-2H-tetrazolium bromide (MTT) assays showed a hormetic effect of ozone: low concentrations could promote cell regeneration, while high concentrations were harmful to cells.

Similar results were observed in the second step of our study, where canine amniotic membrane stem cells were subjected to the same hypoxia-ozonization protocol and evaluated by colorimetric assay spectrophotometry, fluorescence microscopy, and flow cytometry. These results indicated concentration-dependent effects and possibly neuro-regeneration at low concentrations.

Although more studies are needed, our results suggest that *in vitro*, low concentrations were able to reverse the damage caused by hypoxia.

Importantly, our study proposed an unprecedented protocol. In contrast to our study, most other studies use ozone as preconditioning. This is incompatible with what we see in clinical routine, wherein ozone is used as post-stroke therapy.

## MATERIALS AND METHODS

The experiment was divided into two phases performed with neuroblastoma lineage cells and with amniotic membrane stem cells, carried out in Brazil. This project was submitted to the Ethics Committee on the Use of Animals of the Faculty of Animal Science and Food Engineering of the University of São Paulo on August

115 23, 2018 and was approved through protocol CEUA FZEA-USP n. 3722230818 and  
116 CEUA IFSC-USP n. 8689190419.

117 For the first step, SH-SY5Y neuroblastoma lineage cells were grown in bottles  
118 in culture medium (DMEM-high glucose + 10% fetal bovine serum + 1%  
119 penicillin/streptomycin + 1% glutamine) and incubated at 37 °C and 5% CO<sub>2</sub>, for  
120 about 3 or 4 days, until they reached about 90% of confluence. Cells were trypsinized  
121 and counted using Thoma Chamber, with trypan blue. Approximately 1x10<sup>-4</sup> SH-  
122 SY5Y cells, diluted in 200 µL of culture medium, were plated per well in a 96-well  
123 culture plate. Four wells were also plated with the same number of cells on another  
124 plate, as a hypoxia control. The plates were incubated at 37 °C and 5% CO<sub>2</sub> for 24  
125 hours. The experiment was carried out thrice in quadruplicates. After 24 hours, the  
126 culture plate was placed inside an incubation culture chamber. The completely  
127 sealed chamber was filled with about 10% CO<sub>2</sub> + N<sub>2</sub>, and the cells were incubated for  
128 another 24 hours at 37 °C. The control plate (no hypoxia group) was not subjected to  
129 the hypoxia protocol and remained incubated at 37 °C and 5% CO<sub>2</sub> for 24 hours. A  
130 difference in the color of the medium could be observed after 24 hours of hypoxia.

131 After 24 hours, 1.5 mL of culture medium was mixed with 1.5 mL of ozone in a  
132 5 mL syringe and stirred for 5 minutes. Each syringe contained a different  
133 concentration of ozone (2, 5, 10, 15, 20, and 30 µg/mL); an additional syringe  
134 contained only O<sub>2</sub>, while no gas was added to another. The culture medium was  
135 removed from each well of the 96-well plate and replaced with ozonized culture  
136 medium containing different concentrations of ozone, according to the scheme below.  
137 The plate was incubated for another 24 hours. In the control plate, the culture  
138 medium was replaced with normal medium, with no addition of gas.

139 The colorimetric MTT assay was performed to verify cellular metabolic activity.  
140 After 24 hours, in a light-deprived environment, the ozonized medium was replaced  
141 with 200 µL of MTT (0.5 mg/mL diluted in PBS) per well. After a 90-minute  
142 incubation, MTT was removed, and 200 µL of DMSO was added per well. The  
143 absorbance was measured at 690 nm using a spectrophotometer (Multiskan Go  
144 Spectrophotometer - Thermo Fisher Scientific). The spectrophotometry results were  
145 transformed into a percentage, wherein the group not subjected to hypoxia  
146 represented 100%.

147 The experimental design is depicted in Figure 1.

148

149 **Figure 1. Experimental design of protocol for neuroblastoma cells.** Cells were cultured *in vitro*  
150 and subjected to hypoxia. After 24 hours, the culture medium was replaced by ozonized medium at  
151 different concentrations for 5 minutes, incubated for another 24 hours, and then evaluated.

152

153 After satisfactory *in vitro* results with neuroblastoma cells, we decided to  
154 perform the same hypoxia-ozonation protocol with canine amniotic membrane stem  
155 cells, the same cells used in a previously published study (24). These mesenchymal  
156 stem cells are easy to obtain and can be discarded. They are easy to manipulate,  
157 and their proliferation is straightforward. These cells play an essential role in  
158 regenerative medicine, and having been previously characterized by our study group,  
159 prove to be safe for the application (25–28). After elective neutering surgery, the  
160 uterus of a bitch was sent to the laboratory at an early gestational stage. The  
161 amniotic membranes of eight fetuses were collected, as seen in Figure 2.

162

163 **Figure 22. Isolation of canine amniotic membrane stem cells.** A: Fetus in the first-third of the  
164 gestational period surrounded by the placenta. B: Dissection of amniotic membrane. C: Amniotic  
165 membrane in a culture plate.

166

167 Following the protocol by Orlandin et al. (24), membranes were washed in  
168 PBS with penicillin + streptomycin and incubated in 1% collagenase for 2 hours. After  
169 this period, they were centrifuged at 1200 rpm for 10 minutes. The pellet was  
170 resuspended in DMEM-high glucose + 10% fetal bovine serum + 1%  
171 penicillin/streptomycin + 0.5% glutamine, and the cell culture bottles were incubated  
172 at 37 °C and 5% CO<sub>2</sub> for 3 days when they reached approximately 80% confluence.

173 For cell trypsinization, the medium was discarded and the bottle was washed  
174 with PBS. Tryple Express (3 mL; Gibco) were added. The bottle remained in an  
175 incubator for 2 minutes, to allow the cells to detach from the plate. Tryple Express  
176 was collected in a falcon tube, and the bottle was washed with the culture medium to  
177 help detach the remaining cells. This culture medium was collected in the same  
178 falcon and centrifuged at 1500 rpm for 5 minutes. Cells were picked and plated for an  
179 additional 4 days until they reached approximately 90% confluence. The  
180 trypsinization process was repeated, and the cells were counted using Thoma  
181 Chamber, with trypan blue, and harvested according to the specified assay.

182 For each assay, cells were harvested at different concentrations, using  
183 different plates, and at different volumes. Corresponding specifications are presented  
184 for each assay. Regardless, all of them were subjected to the same hypoxia protocol,  
185 as described below. All experiments were performed in triplicate and repeated three  
186 times. In addition to the experimental wells, separate wells were set aside for  
187 negative and positive control, for each protocol.

188 After 24 hours, the culture plate was placed inside a completely sealed  
189 incubator culture chamber, filled with about 10% CO<sub>2</sub> + 90% N<sub>2</sub>, and incubated for  
190 another 24 hours. The control plate did not go through the hypoxia protocol and was  
191 incubated at 37 °C and 5% CO<sub>2</sub> for another 24 hours.

192 After 24 hours, a 20-mL syringe filled with 10 mL of culture medium was  
193 attached to an ozone generator (Ozone Generator O&L 3.0 RM – Ozone & Life Ltda  
194 – Brazil – ref 301140366), which injected another 10 mL of the gas into the syringe.  
195 They were stirred for 5 minutes. Each syringe contained a different concentration of  
196 ozone: 3, 8, 12, 18, and 30 µg/mL; additionally, a syringe with 10 mL of O<sub>2</sub> and  
197 another without the addition of any gas (no gas group) were included.

198 The culture medium in each well was replaced by the ozonized medium at  
199 different concentrations. The plate was incubated for another 24 hours. In the control  
200 plate (no hypoxia group), the culture medium was replaced by a normal medium with  
201 no gas addition.

202 For the MTT assay, the above protocol was used. The absorbance was  
203 measured at 690 nm using a spectrophotometer (BioTek Epoch 2 microplate  
204 Spectrophotometer). The spectrophotometry results were transformed into  
205 percentage values, where the group not subjected to hypoxia represented 100%.

206 For the superoxide dismutase (SOD) and catalase (CAT) quantification, 1x10<sup>-5</sup>  
207 cells were inoculated in a 6-well plate in 3 mL of culture medium per well in triplicate  
208 and subjected to the hypoxia-ozonation protocol, as mentioned above. The same  
209 plate was used for evaluating SOD (Superoxide Dismutase Colorimetric Activity Kit –  
210 Thermo Fisher Scientific – ref EIASODC) and CAT (Catalase Colorimetric Activity Kit  
211 –Thermo Fisher Scientific – ref EIACATC) activities, as only the medium was used to  
212 perform the SOD assay. In contrast, the cells were used to perform the CAT assay.  
213 The substrates were added, and the plate was incubated according to the  
214 manufacturer's instructions. The absorbance was read at 450 nm and 520 nm by a  
215 spectrophotometer for SOD and CAT quantification, respectively.



216 For the apoptosis detection, we performed the TUNEL test, where  $1 \times 10^{-3}$  cells  
217 were harvested in a 96-well plate in 200  $\mu$ L of culture medium per well in duplicate  
218 and subjected to the hypoxia-ozone protocol, as mentioned above. Using the  
219 commercial Click-iT TUNEL (In Situ Cell Death Detection Kit, Fluorescein – Sigma-  
220 Aldrich – ref 11684795910) colorimetric detection kit, following the manufacturer's  
221 instructions, the culture medium was removed and the cells were fixed with 4%  
222 paraformaldehyde and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate.  
223 TUNEL mixing solution (50  $\mu$ L) was added to each sample and the positive and  
224 negative controls. The plate was incubated in an oven for 60 minutes, washed with  
225 PBS three times, and 200  $\mu$ L of PBS was added for microscopic analysis. The cells  
226 were analyzed using a digital inverted EVOS microscope (Microscope EVOS™ FLc  
227 M5000 Imaging System – Thermo Fisher Scientific – ref AMEP4650) with a GFP  
228 laser (470 nm excitation/525 nm emission). The images were analyzed via  
229 fluorescence intensity quantification using ImageJ software, with intensity assignment  
230 between 0 and 200 per pixel.

231 The Image-iT® Lipid Peroxidation Kit has a lipid peroxidation sensitive agent.  
232 After oxidation, the fluorescence changes from red to green, allowing its  
233 quantification. For the lipid peroxidation assay,  $2.5 \times 10^{-4}$  cells were harvested in a 24-  
234 well plate in 1 mL of culture medium per well in triplicate and subjected to the  
235 hypoxia-ozone protocol, as mentioned above. Image-iT® Lipid Peroxidation  
236 Sensor (10  $\mu$ M; Image-iT Lipid Peroxidation Kit – Thermo Fisher Scientific – ref  
237 C10445) was added, and the plate was incubated at 37 °C for 30 minutes in the dark.  
238 The culture medium was removed, and the plate was washed 3 times with PBS; 1 mL  
239 of PBS was added per well. As observable in Figure 15, the cells were analyzed with  
240 a digital inverted EVOS microscope, with a Texas Red laser (585 nm excitation/624  
241 nm emission) and GFP (470 nm excitation/525 nm emission). The excitation and  
242 emission were adjusted for each probe. Cells were trypsinized and immediately read  
243 using a BD Accuri C6 flow cytometer (BD Accuri™ C6 Flow Cytometer – BD  
244 Biosciences – ref 7820018).

245 CellROX® Green is a fluorogenic probe that after oxidation, binds to DNA,  
246 rendering the nucleus and mitochondria fluorescent. For the ROS assay,  $2.5 \times 10^{-4}$   
247 cells were harvested in a 24-well plate in 1 mL of culture medium per well in triplicate  
248 and subjected to the hypoxia-ozone protocol, as mentioned above. CellROX  
249 Green (10  $\mu$ M; CellROX Green Reagent, for oxidative stress detection – Thermo



250 Fisher Scientific – ref C10444) reagent working dye solution was added to the culture  
251 medium of each well, followed by incubation at 37 °C for 30 minutes in the dark. The  
252 culture medium was removed, and the plate was washed thrice with PBS; 1 mL of  
253 PBS was added per well. The cells were analyzed using a digital inverted EVOS  
254 microscope with a GFP laser (470 nm excitation/525 nm emission). Cells were  
255 trypsinized and read using a BD Accuri flow cytometer.

256 CellTracker™ Blue fluorescent probes cross the cell membrane and are  
257 transferred to daughter cells but not adjacent cells in a population. Therefore, they  
258 are an important tool for monitoring chemotaxis and cell proliferation. As it presents a  
259 reaction mediated by glutathione S-transferase, CellTracker Blue probes have also  
260 been used for GSH quantification (29,30). For the GSH assay,  $1 \times 10^4$  cells were  
261 harvested in a 24-well plate in 1 mL of culture medium per well in duplicate and  
262 subjected to the hypoxia-ozonation protocol, as mentioned above. The culture  
263 medium was removed, and a solution containing 10 µM of CellTracker Blue  
264 (CellTracker Blue CMF2HC (Molecular Probes) – Thermo Fisher Scientific – ref  
265 C12881) in DMSO was added to each well. The plate was incubated for 30 minutes  
266 at 37 °C in the dark. The solution was removed, and 1 mL of PBS was added per  
267 well. The cells were analyzed using a digital inverted EVOS microscope with a tgBFP  
268 laser (390 nm excitation/447 nm emission). Cells were trypsinized and read using a  
269 BD FACSARIA flow cytometer (BD FACSARIA™ II Flow Cytometer Cell Sorter).

270 For all of the tests, data were analyzed using Prism 5.0. Tests for normality of  
271 residuals and homogeneity of variances were performed for each variable (body  
272 weight, clinical evaluation, and cerebral infarction volume). Data that did not meet the  
273 ANOVA assumptions were transformed. Statistical analysis of total infarct volume  
274 data was performed using the one-Way ANOVA test, a non-parametric statistic for  
275 purchasing groups, followed by Tukey's Post-hoc test, considering the significance  
276 level ( $p < 0.05$ ). The results are expressed as mean  $\pm$  standard error of the mean.

277

## 278 RESULTS

279

## 280      **Spectrophotometry suggests cell regeneration at low ozone concentrations** 281      **and apoptosis at high ozone concentrations**

282

283      As expected, the neuroblastoma cells that suffered hypoxia, but received the  
284      culture medium without the addition of any gas, presented lower metabolic activity  
285      with respect to the control cells, which were not subjected to hypoxia. These results  
286      indicate that the protocol resulted in partial cell death, although it was not statistically  
287      significant ( $p>0.05$ ). Cells treated with low concentrations of ozone (2  $\mu\text{g/mL}$ ) showed  
288      higher rates of cell viability than those that were subjected to hypoxia but did not  
289      receive any treatment or only received oxygen ( $p<0.05$ ). This indicates that the  
290      treatment not only reversed the effects of ischemia but also promoted cell  
291      regeneration in these cells. Furthermore, cells treated with 2  $\mu\text{g/mL}$  ozone were  
292      significantly similar to those not subjected to hypoxia and those treated with 5 and 10  
293       $\mu\text{g/mL}$  ozone ( $p>0.05$ ), showing that these low concentrations are safe and maintain  
294      high rates of cell viability. Cells subjected to hypoxia that received no gas or only  
295      oxygen had the same cellular viability rate as those treated with 15 and 20  $\mu\text{g/mL}$  of  
296      ozone ( $p>0.05$ ). Finally, cells treated with 30  $\mu\text{g/mL}$  of ozone showed a decrease in  
297      cell viability ( $p<0.05$ ), indicating that high concentrations of ozone can harm cells.

298      Amniotic membrane stem cells (AMSC) treated with 3  $\mu\text{g/mL}$  of ozone showed  
299      no significant difference compared to cells that did not undergo the hypoxia protocol  
300      ( $p>0.05$ ). Additionally, these cells are similar to those that received no gas, received  
301      only oxygen, or were treated with 8  $\mu\text{g/mL}$  ozone ( $p>0.05$ ). Cells treated with low  
302      concentrations of ozone (2–8  $\mu\text{g/mL}$ ) showed better cell metabolism, compared to  
303      cell metabolism noted for other ozone treatments (12–30  $\mu\text{g/mL}$ ) ( $p<0.05$ ), implying  
304      that these concentrations are safe and do not promote cell damage. Treating cells  
305      with 18 and 30  $\mu\text{g/mL}$  of ozone harmed them, promoting cellular apoptosis compared  
306      to the cells in other groups ( $p<0.05$ ). These results corroborate the results of the  
307      experiments conducted on our neuroblastoma cell lineages.

308      SOD analyses were performed on the culture medium and not on the cells.  
309      They were intended to mimic a serological quantification of SOD emitted by cells.  
310      SOD activity is associated with the cellular ability to scavenge free radicals. All  
311      ozone-treated groups had SOD levels comparable to cells not subjected to hypoxia  
312      ( $p>0.05$ ). Cells that were subjected to hypoxia but received no gas or only oxygen  
313      had higher levels of SOD when compared to the group without hypoxia ( $p<0.05$ ). It is

important to emphasize that the commercial kit allows the quantification of SOD-1 and SOD-2, which are intracellular and mitochondrial enzymes, and SOD-3, which is extracellular and can be detected in serum, plasma, ascites, and synovial fluids. We tried to standardize a protocol for quantifying SOD in the culture medium to mimic the serological levels of the enzyme. Nonetheless, the results are inconsistent, and we do not consider them to be representative.

We observed a significant decrease in catalase rate following the increase in ozone concentration. Catalase levels of cells not subjected to hypoxia were significantly similar to those treated with no gas, only oxygen, and 3 and 8  $\mu\text{g/mL}$  ozone ( $p>0.05$ ). Cells treated with 30  $\mu\text{g/mL}$  of ozone had the lowest levels of the intracellular enzyme, followed by cells of the groups treated with 18 and 12  $\mu\text{g/mL}$  ozone, all of which presented significant differences between each other ( $p<0.05$ ). This probably occurred due to the cytotoxic effect of ozone at high concentrations, as one of its by-products is hydrogen peroxide, a substance degraded by the peroxidase under study.

The spectrophotometry results have been presented in Figure 3.

**Figure 33. SH-SY5Y MTT (A) and AMSC MTT (A), SOD (B), and CAT (C) quantification, where  $p<0.05$ .** During the MTT test, cells not subjected to the hypoxia protocol were considered 100%. We observed a pattern of reversal of the hypoxia effect and the promotion of cell regeneration at low ozone concentrations. Cellular apoptosis at high ozone concentrations was prominent in both kinds of cells (A and B). We also observed that SOD spectrophotometry results were inconsistent (C) and that high ozone concentrations promoted a decrease in catalase rate after hypoxia induction (D).

### **Apoptosis detection assay corroborated the MTT data for high ozone concentrations promoting cell death**

Due to material supply problems during the pandemic, we could not receive the TUNEL Kit in time to perform the tests. To this end, we borrowed two kits from a teacher at the institution. One of the kits was outdated and did not yield good images. Due to material limitations, cells grown in 96-microwell plates could not be subjected to flow cytometry. Therefore, the results could only be obtained from one sample from each group (Figure 4), and we could not perform duplicates or triplicates. Forty

cells from each group were evaluated using ImageJ software for fluorescence rate (grey-value), resulting in the following graph.

**Figure 4. The higher the ozone level, the higher the rate of cell apoptosis.** A: Representative pictures of cell apoptosis measured by TUNEL assay. C: Quantification of cell apoptosis (Gray-value, calculated by ImageJ), where  $p < 0.05$ .

Cells that were not subjected to hypoxia showed the lowest levels of cellular apoptosis compared to the other groups ( $p < 0.05$ ). Cells treated with 3 or 8  $\mu\text{g/mL}$  of ozone showed higher levels of cellular apoptosis than the cells in the no hypoxia group but lower levels than the cells in other groups ( $p < 0.05$ ). Cells subjected to hypoxia, but not receiving any gas, behaved similarly to those receiving oxygen ( $p > 0.05$ ). Nevertheless, they exhibited a lower rate of cellular apoptosis than cells of groups treated with 18 or 30  $\mu\text{g/mL}$  ( $p < 0.05$ ). Cells treated with 30  $\mu\text{g/mL}$  of ozone showed the highest rates of cell apoptosis compared to cells of all other groups ( $p < 0.05$ ).

These results are consistent with those of the MTT assay, wherein the mortality rate was higher in the groups treated with high ozone concentrations.

## **No significant differences were observed in lipid peroxidation**

The Image-iT® Lipid Peroxidation Kit has a lipid peroxidation sensitive agent. After oxidation, the fluorescence changes from red to green, allowing its quantification. As noted, the assessment of lipid peroxidation did not reveal significant differences between any of the groups ( $p > 0.05$ ). The results have been presented in Figure 5.

**Figure 5. No treatment was of significant importance for lipid peroxidation.** A: Representative pictures of lipidic peroxidation measured by Image-iT assay. B: Non-oxidized cells (red) and oxidized cells (green) measured by flow cytometry. C: Quantifying oxidized and non-oxidized cells (Q2-UR), where  $p < 0.05$ .

## Low ozone concentration did not change ROS levels

CellROX® Green is a fluorogenic probe that after oxidation, binds to DNA, making the nucleus and mitochondria fluorescent. The results are presented in Figure 6.

### Figure 6. Low ozone concentrations do not increase the rate of reactive oxygen species (ROS).

A: Representative pictures of ROS, as detected via CellROX Green assay. B: ROS examined via flow cytometry (FL1). C: Quantification of ROS levels, where  $p < 0.05$ .

According to the analyses, low concentrations of ozone (3 and 8  $\mu\text{g/mL}$ ) did not show changes in ROS levels, compared to groups that were not subjected to hypoxia without gas and oxygen ( $p > 0.05$ ). Only the groups treated with 12 or 18  $\mu\text{g/mL}$  of ozone presented reduced levels of ROS, compared to the other groups ( $p < 0.05$ ). ROS levels increased again in cells treated with 30  $\mu\text{g/mL}$  ozone, equaling the levels noted for the other groups ( $p > 0.05$ ).

## Reduced Glutathione (GSH) levels remain unchanged across groups

The results presented below (Figure 7) show no significant differences between samples ( $p > 0.05$ ) for reduced GSH.

### Figure 74. No treatment showed a significant difference in reduced glutathione level. A:

Representative pictures of reduced glutathione (GSH) measured by CellTracker Blue assay. B: Reduced GSH measured by flow cytometry. C: Quantification of reduced GSH (DAPI), where  $p < 0.05$ .

Importantly, these CellTracker™ Blue fluorescent probes are intended to stain daughter cells to screen the cell population. Few studies have used this probe to quantify GSH, owing to the reaction mediated by glutathione S-transferase. However, we reiterate that this is not the purpose recommended by the manufacturer (29,30).

Another critical point is that this technique was performed only in duplicate, with a very limited number of cells ( $1 \times 10^3$  events). The data is unreliable and

412 inconsistent. We do not recommend using the CellTracker™ Blue probe to quantify  
413 GSH in cells under the conditions discussed in this manuscript.

414

## 415 **DISCUSSION**

416

417 In the present study, neuroblastoma cells and canine amniotic membrane stem  
418 cells were cultured *in vitro* and subjected to a 24-hour protocol in hypoxia to simulate  
419 an ischemic injury. Subsequently, the culture medium of cells was treated with  
420 different ozone concentrations, and the cellular response was evaluated.

421 Although ozone-mediated oxidative stress can contribute to the pathogenesis of  
422 neurodegenerative diseases (31), it is also known that mild, controlled, and targeted  
423 oxidative stress can be beneficial and can improve performance (32). Therefore,  
424 ozone is said to have a dose-dependent hormetic effect (10,12,33–38).

425 Corroborating the results of these studies, an MTT assay of neuroblastoma cells  
426 treated with post-hypoxia ozone indicated that low concentrations of ozone (2–10  
427 µg/mL) were able to repair the effects of ischemia and promoted cell regeneration.  
428 This result is consistent with those of the MTT assay for canine amniotic membrane  
429 stem cells that underwent the same protocol. The group treated with 3–8 µg/mL  
430 showed improved cell metabolism. The results of TUNEL assay indicated that  
431 apoptosis rates are lower in cells treated with low ozone concentration (3–8 µg/mL).  
432 In all these trials, the harmful effects of ozone were observed at high concentrations  
433 (18–30 µg/mL), which promoted higher rates of apoptosis and cell death.

434 An increase in SOD levels after ozone treatment has been described previously  
435 (21,39,40). We attempted to develop a protocol for measuring SOD levels in a cell  
436 culture medium using the SOD Colorimetric Activity Kit (Thermo Fisher Scientific) to  
437 simulate serological levels of the enzyme. However, our results were inconsistent,  
438 and we could not conclusively comment on whether ozone-treated groups showed an  
439 increase or decrease in SOD levels. We recommend that such analysis be performed  
440 with these cells in the future, according to the manufacturer's guidelines.

441 In contrast with some prior studies (21,39), we observed a progressive decrease  
442 in CAT levels as we increased the ozone concentration. CAT levels are an indicator  
443 of mitochondrial oxidative stress. Therefore, we expected increased CAT levels  
444 proportional to the increase in ozone concentration. Nevertheless, the same studies

demonstrated a decrease in SOD and CAT levels after ischemia/reperfusion (IR). We reinforce here that our study involved usage of post-hypoxia ozone, and we believe that this may explain the observed inversion of CAT levels. We also suggest that the unexpected levels of CAT could be due to the reduction in the number of cells caused by gradual cell death with increasingly higher ozone doses.

As reported in other studies (41,42), we expected to observe an increase in lipid peroxidation corresponding to an increase in ozone concentration. Instead, in our study, the evaluation of lipid peroxidation (LPO) did not result in significant increase among any of the groups studied.

The quantification of ROS levels after hypoxia revealed no difference in the control and low ozone-treated groups (3 and 8  $\mu\text{g/mL}$ ). The groups treated with 12 or 18  $\mu\text{g/mL}$  of ozone showed a significant decrease in ROS levels, which increased again in the group treated with 30  $\mu\text{g/mL}$ , still being comparable with ROS levels noted for other groups. We expected to observe an increase in ROS levels, as it is one of the by-products of ozone, and the higher its concentration, the greater should be the production of ROS (43–47).

To quantify levels of reduced GSH, we used a protocol detailed in King et al. (29) and Casaril et al. (30), using CellTracker™ Blue fluorescent probes (Thermo Fisher Scientific). We restate that these probes, according to the manufacturer, are intended to stain daughter cells to screen a cell population. The data obtained were unreliable and inconsistent. We do not recommend using CellTracker™ Blue probe to quantify GSH in cells under the conditions discussed in this manuscript.

Few studies have evaluated the effect of ozone as a treatment for *in vitro* ischemia. Most studies used ozone for preconditioning cells, which were subjected to hypoxia only after treatment with the gas (39,40,48–53). Similar to our study, Cai et al. (21) used ozone after inducing hypoxia. However, they trypsinized the cells to perform the ozonation and re-plated them at a concentration stipulated for all groups.

In our study, all groups were initially plated at the same cell concentration. The culture plates were subjected to hypoxia. The cells themselves were not ozonized, but the cell culture medium was. We attempted to re-create the events of an ischemic stroke, wherein brain cells do not receive the gas, and instead, receive its by-products via the bloodstream. In addition, in real life, hardly any patient has sought treatment before disease onset. Patients who have suffered from ischemia and have survived seek therapies to minimize its sequelae. A literature survey did not reveal



any publication using this protocol. Therefore, our study has pioneered the protocol for mimicking the *in vitro* consequences to a tissue treated with ozone therapy after suffering hypoxia.

Some professionals are against the practice of ozone therapy, owing to concerns regarding the toxicity of ozone at any concentration; however, such a perspective disregards the foundations of physiology and toxicology, as well as the advances in research and science. (46). Ozone therapy has been scientifically proven to be effective and safe, and thus, it should be considered a practical alternative by the relevant practitioners and researchers. Many of the studies presented on this topic have incomplete data, which impedes the standardization of the technique and the results obtained (46,54). We believe that these results should be shared and discussed to understand the technique and its mechanisms.

One of the recently raised hypotheses about the mechanisms of ozone therapy relates to its effect on blood cells and the extracellular matrix of the intravascular compartment (47). The interaction of ozone with blood cells and blood plasma during major autohemotherapy (when the blood of the ozonated patient is reinfused intravenously), resulting in LPO, primarily 4-hydroxynonenal (4-HNE); 4-HNE activates a cascade in the vascular endothelium, resulting in the release of nitric oxide, which acts as a vasodilator, and the upregulation of oxidative stress proteins and antioxidant enzymes to protect the vascular matrisome. With the intent of expanding such research efforts for application in clinical routine and considering that ischemic stroke is primarily a vascular disease, we believe that these factors should be examined in future research.

502

## 503 CONCLUSION

504

To conclude, we reported a novel protocol, which involves using ozone after cell damage, as doing so is closer to the real-world scenario experienced by patients.

507

It is possible to perform *in vitro* post-hypoxia ozone therapy in cell cultures, without the need to resuspend them, simulating an ischemic stroke.

*In vitro*, low concentrations of ozone (2–10 µg/mL) enhanced the cellular metabolism of a neuronal cell line, which may be suggestive of post-hypoxia cell

512 regeneration and reversal of cellular damage caused by hypoxia. High ozone  
513 concentrations (above 18 µg/mL) *in vitro* can cause cell damage.

514 Therefore, ozone exhibits a dose-dependent hormetic effect, and at low  
515 concentrations, is capable of reversing the effect of ischemia *in vitro*.

516 Although further studies are warranted, the use of ozone may be a promising  
517 therapeutic alternative for treating sequelae in stroke patients. Nevertheless, the  
518 concentration of ozone is an essential factor to be considered before prescribing  
519 treatment, especially in post-hypoxia conditions, wherein the cells are already  
520 damaged.

521

## 522 **ACKNOWLEDGMENTS**

523

524 We would like to thank CAPES (PrInt No.88887.371111/2019-00) and FAPESP  
525 (No. 2018/24552-6) for their institutional support and Ozone & Life Ltda for providing  
526 us with the ozone generator used in our experiments. We also thanks Professor  
527 Fernando Fernandes Paiva and his team at Instituto de Física de São Carlos (IFSC-  
528 USP); the doctors Maria Serena Milella and Jasmine Ercoli; and the Professor  
529 Federica Pessina, Luana Ricci Paulesu e Maria Frosini from the University of Siena  
530 for their support.

531

## 532 **REFERENCES**

533

- 534 1. Klijn CJ, Kappelle LJ. Haemodynamic stroke: clinical features, prognosis, and  
535 management. *The Lancet Neurology* . 2010;9(10):1008–17. Available from:  
536 <http://www.ncbi.nlm.nih.gov/pubmed/20864053>
- 537 2. Jones F, Riazi A. Self-efficacy and self-management after stroke: a systematic  
538 review. *Disability and Rehabilitation* . 2011;33(10):797–810. Available from:  
539 <http://www.ncbi.nlm.nih.gov/pubmed/20795919>
- 540 3. Doyle PJ. Measuring health outcomes in stroke survivors. *Archives of Physical*  
541 *Medicine and Rehabilitation*. 2002;83:S39–43. Available from:  
542 <http://linkinghub.elsevier.com/retrieve/pii/S0003999302006238>

- 543 4. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW,  
544 et al. Heart Disease and Stroke Statistics—2021 Update. *Circulation*.  
545 2021;E254–743. Available from:  
546 <https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000950>
- 547 5. Sumer M, Ozdemir I, Erturk O. Progression in acute ischemic stroke:  
548 Frequency, risk factors and prognosis. *Journal of Clinical Neuroscience*.  
549 2003;10(2):177–80. Available from:  
550 <https://www.sciencedirect.com/science/article/pii/S0967586802003259>
- 551 6. Lim SH, Lee JS, Lee JI, Im S, Ko YJ, Kim HW. The quantitative assessment of  
552 functional impairment and its correlation to infarct volume in rats with transient  
553 middle cerebral artery occlusion. *Brain Research*. 2008;1230:303–9. Available  
554 from: <http://www.ncbi.nlm.nih.gov/pubmed/18675259>
- 555 7. Menzies SA, Hoff JT, Betz AL. Middle Cerebral Artery Occlusion in Rats.  
556 *Neurosurgery*. 1992;31(1):100–7. Available from:  
557 <https://academic.oup.com/neurosurgery/article/31/1/100/2751985>
- 558 8. Sagai M, Bocci V. Mechanisms of Action Involved in Ozone Therapy: Is healing  
559 induced via a mild oxidative stress? *Medical Gas Research*. 2011;1(1):29.  
560 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22185664>
- 561 9. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on  
562 the effects of ozone on blood. *International Journal of Biological*  
563 *Macromolecules*. 2007;41(5):504–11. Available from:  
564 <https://www.sciencedirect.com/science/article/pii/S0141813007001675>
- 565 10. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: Ozone is a  
566 strong oxidant as well as a medical drug. *Medicinal Research Reviews*.  
567 2009;29(4):646–82. Available from:  
568 <http://www.ncbi.nlm.nih.gov/pubmed/19260079>
- 569 11. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, et al.  
570 The Nrf2-ARE Pathway. *Ann N Y Acad Sci*. 2008;1147(1):61–9. Available from:  
571 <http://www.ncbi.nlm.nih.gov/pubmed/19076431>
- 572 12. Bocci V, Zanardi I, Travagli V. Oxygen/ozone as a medical gas mixture. A  
573 critical evaluation of the various methods clarifies positive and negative  
574 aspects. *Medical Gas Research*. 2011;1:1–6. Available from:  
575 </pmc/articles/PMC3231820/?report=abstract>

- 576 13. Tufekci KU, Civi Bayin E, Genc S, Genc K. The Nrf2/ARE Pathway: A  
577 Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's  
578 Disease. *Parkinson's Disease*. 2011;2011:1–14. Available from:  
579 <http://www.ncbi.nlm.nih.gov/pubmed/21403858>
- 580 14. Frosini M, Contartese A, Zanardi I, Travagli V, Bocci V. Selective ozone  
581 concentrations may reduce the ischemic damage after a stroke. *Free Radical*  
582 *Research*. 2012;46(5):612–8. Available from:  
583 <http://www.ncbi.nlm.nih.gov/pubmed/22263539>
- 584 15. Fuccio C, Luongo C, Capodanno P, Giordano C, Scafuro MA, Siniscalco D, et  
585 al. A single subcutaneous injection of ozone prevents allodynia and decreases  
586 the over-expression of pro-inflammatory caspases in the orbito-frontal cortex of  
587 neuropathic mice. *Eur J Pharmacol*. 2009;603(1–3):42–9. Available from:  
588 <http://www.ncbi.nlm.nih.gov/pubmed/19100257>
- 589 16. Ozbay I, Ital I, Kucur C, Akcılar R, Deger A, Aktas S, et al. Effects of ozone  
590 therapy on facial nerve regeneration. *Braz J Otorhinolaryngol*. 2017;83(2):168–  
591 75. Available from: [www.bjorl.org](http://www.bjorl.org)
- 592 17. Ozturk O, Tezcan AH, Adali Y, Yıldırım CH, Aksoy O, Yagmurdu H, et al.  
593 Effect of ozone and methylprednisolone treatment following crush type sciatic  
594 nerve injury. *Acta Cirurgica Brasileira*. 2016;31(11):730–5. Available from:  
595 [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S0102-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502016001100730&lng=en&tlng=en)  
596 [86502016001100730&lng=en&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502016001100730&lng=en&tlng=en)
- 597 18. Somay H, Emon ST, Uslu S, Orakdogan M, Meric ZC, Ince U, et al. The  
598 Histological Effects of Ozone Therapy on Sciatic Nerve Crush Injury in Rats.  
599 *World Neurosurgery*. 2017;105:702–8. Available from:  
600 <https://www.sciencedirect.com/science/article/pii/S187887501730863X>
- 601 19. Yucesoy T, Kutuk N, Canpolat DG, Alkan A. Comparison of Ozone and Photo-  
602 Biomodulation Therapies on Mental Nerve Injury in Rats. *Journal of Oral and*  
603 *Maxillofacial Surgery*. 2017;75(11):2323–32. Available from:  
604 <http://www.ncbi.nlm.nih.gov/pubmed/28529151>
- 605 20. Tricarico G, Isakovic J, Song M, Rustichelli F, Travagli V, Mitrecic D. Ozone  
606 influences migration and proliferation of neural stem cells in vitro. *Neurosci*  
607 *Lett*. 2020;739. Available from: <https://pubmed.ncbi.nlm.nih.gov/32947004/>
- 608 21. Cai H, Tao X, Zheng L, Huang L, Peng Y, Liao R, et al. Ozone alleviates  
609 ischemia/reperfusion injury by inhibiting mitochondrion-mediated apoptosis

- 610 pathway in SH-SY5Y cells. Cell Biology International. 2020;44(4):975–84.  
611 Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/cbin.11294>
- 612 22. Clavo B, Catalá L, Pérez JL, Rodríguez V, Robaina F. Ozone Therapy on  
613 Cerebral Blood Flow: A Preliminary Report. Evid Based Complement Alternat  
614 Med. 2004;1(3):315–9. Available from:  
615 <http://www.ncbi.nlm.nih.gov/pubmed/15841265>
- 616 23. Zhou N bao, Fu Z jian, Sun T. Effects of different concentrations of oxygen –  
617 ozone on rats’ astrocytes in vitro. Neuroscience Letters. 2008;441(2):178–82.
- 618 24. Orlandin JR, Gomes I da S, Leandro S de FS, Cagnim AF, Casals JB,  
619 Carregaro AB, et al. Treatment of Chronic Spinal Cord Injury in Dogs Using  
620 Amniotic Membrane-Derived Stem Cells: Preliminary Results. Stem Cells and  
621 Cloning: Advances and Applications. 2021;14:39–49. Available from:  
622 [https://www.dovepress.com/treatment-of-chronic-spinal-cord-injury-in-dogs-](https://www.dovepress.com/treatment-of-chronic-spinal-cord-injury-in-dogs-using-amniotic-membran-peer-reviewed-fulltext-article-SCCAA)  
623 [using-amniotic-membran-peer-reviewed-fulltext-article-SCCAA](https://www.dovepress.com/treatment-of-chronic-spinal-cord-injury-in-dogs-using-amniotic-membran-peer-reviewed-fulltext-article-SCCAA)
- 624 25. Cardoso M, Pinheiro A, Vidane A, Casals J, de Oliveira V, Gonçalves N, et al.  
625 Characterization of teratogenic potential and gene expression in canine and  
626 feline amniotic membrane-derived stem cells. Reproduction in Domestic  
627 Animals. 2017;52:58–64. Available from:  
628 <http://doi.wiley.com/10.1111/rda.12832>
- 629 26. Vidane A, Pinheiro A, Casals J, Passarelli D, Hage M, Bueno R, et al.  
630 Transplantation of amniotic membrane-derived multipotent cells ameliorates  
631 and delays the progression of chronic kidney disease in cats. Reproduction in  
632 Domestic Animals. 2017;52:316–26. Available from:  
633 <http://www.ncbi.nlm.nih.gov/pubmed/27774657>
- 634 27. Ambrosio C, Vidane A, Souza A, Sampaio R, Bressan F, Pieri N, et al. Cat  
635 amniotic membrane multipotent cells are nontumorigenic and are safe for use  
636 in cell transplantation. Stem Cells and Cloning: Advances and Applications.  
637 2014;7:71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25249758>
- 638 28. Pinheiro A de O, Lara VM, Souza AF, Casals JB, Bressan FF, Neto PF, et al.  
639 Characterization and Immunomodulation of Canine Amniotic Membrane Stem  
640 Cells. Stem Cells and Cloning: Advances and Applications. 2020;13:43–55.  
641 Available from: [https://www.dovepress.com/characterization-and-](https://www.dovepress.com/characterization-and-immunomodulation-of-canine-amniotic-membrane-stem-peer-reviewed-fulltext-article-SCCAA)  
642 [immunomodulation-of-canine-amniotic-membrane-stem-peer-reviewed-fulltext-](https://www.dovepress.com/characterization-and-immunomodulation-of-canine-amniotic-membrane-stem-peer-reviewed-fulltext-article-SCCAA)  
643 [article-SCCAA](https://www.dovepress.com/characterization-and-immunomodulation-of-canine-amniotic-membrane-stem-peer-reviewed-fulltext-article-SCCAA)

- 644 29. King N, Korolchuk S, McGivan JD, Suleiman MS. A new method of quantifying  
645 glutathione levels in freshly isolated single superfused rat cardiomyocytes. J  
646 Pharmacol Toxicol Methods. 2004;50(3):215–22. Available from:  
647 <https://pubmed.ncbi.nlm.nih.gov/15519908/>
- 648 30. Casaril AM, Segatto N, Simões L, Paschoal J, Domingues M, Vieira B, et al.  
649 Neuroprotective Effect of 3-[(4-Chlorophenyl)sulfonyl]-1-methyl-1H-indole on  
650 Hydrogen Peroxide-Induced Oxidative Stress in SH-SY5Y Cells.  
651 Neurochemical Research. 2021;46(3):535–49. Available from:  
652 <https://link.springer.com/article/10.1007/s11064-020-03190-0>
- 653 31. Moldogazieva NT, Mokhosev IM, Mel'Nikova TI, Porozov YB, Terentiev AA.  
654 Oxidative Stress and Advanced Lipoxidation and Glycation End Products  
655 (ALEs and AGEs) in Aging and Age-Related Diseases. Oxidative Medicine and  
656 Cellular Longevity. 2019;2019. Available from: [/pmc/articles/PMC6710759/](https://pubmed.ncbi.nlm.nih.gov/3110759/)
- 657 32. Berry R, López-Martínez G. A dose of experimental hormesis: When mild  
658 stress protects and improves animal performance. Comparative Biochemistry  
659 and Physiology Part A: Molecular & Integrative Physiology. 2020;242:110658.
- 660 33. Bocci VA, Zanardi I, Travagli V. Ozone acting on human blood yields a  
661 hormetic dose-response relationship. Journal of Translational Medicine.  
662 2011;9(1):66. Available from: [https://translational-](https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-66)  
663 [medicine.biomedcentral.com/articles/10.1186/1479-5876-9-66](https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-66)
- 664 34. Bocci V. The Potential Toxicity of Ozone: Side Effects and Contraindications of  
665 Ozonotherapy. In: OZONE. Dordrecht: Springer Netherlands; 2010. p. 75–84.  
666 Available from: [http://link.springer.com/10.1007/978-90-481-9234-2\\_7](http://link.springer.com/10.1007/978-90-481-9234-2_7)
- 667 35. Bocci V. How Does Ozone Act? How and Why Can We Avoid Ozone Toxicity?  
668 In: OZONE. Dordrecht: Springer Netherlands; 2010. p. 17–26. Available from:  
669 [http://link.springer.com/10.1007/978-90-481-9234-2\\_4](http://link.springer.com/10.1007/978-90-481-9234-2_4)
- 670 36. Bocci V. Physical-Chemical Properties of Ozone – Natural Production of  
671 Ozone: The Toxicology of Ozone. In: OZONE. Dordrecht: Springer  
672 Netherlands; 2010. p. 1–4. Available from:  
673 [http://link.springer.com/10.1007/978-90-481-9234-2\\_1](http://link.springer.com/10.1007/978-90-481-9234-2_1)
- 674 37. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicology  
675 and Applied Pharmacology. 2006;216(3):493–504. Available from:  
676 <https://pubmed.ncbi.nlm.nih.gov/16890971/>





- 677 38. Frosini M, Contartese A, Zanardi I, Travagli V, Bocci V. Selective ozone  
678 concentrations may reduce the ischemic damage after a stroke. *Free Radical*  
679 *Research*. 2012;46(5):612–8. Available from:  
680 <http://www.tandfonline.com/doi/full/10.3109/10715762.2012.659247>
- 681 39. Onal O, Yetisir F, Sarer AES, Zeybek ND, Onal CO, Yurekli B, et al.  
682 Prophylactic Ozone Administration Reduces Intestinal Mucosa Injury Induced  
683 by Intestinal Ischemia-Reperfusion in the Rat. *Mediators of Inflammation*.  
684 2015;2015. Available from: [/pmc/articles/PMC4487723/](https://pubmed.ncbi.nlm.nih.gov/264487723/)
- 685 40. Rodríguez ZZ, Guanche D, Álvarez RG, Rosales FH, Alonso Y, Schulz S.  
686 Preconditioning with ozone/oxygen mixture induces reversion of some  
687 indicators of oxidative stress and prevents organic damage in rats with fecal  
688 peritonitis. *Inflamm Res*. 2009;58(7):371–5. Available from:  
689 <https://pubmed.ncbi.nlm.nih.gov/19274439/>
- 690 41. Laszczyca P, Kawka-Serwecińska E, Witas I, Dolozych B, Falkus B, Mekail A,  
691 et al. Lipid peroxidation and activity of antioxidative enzymes in the rat model of  
692 ozone therapy. *Materia Medica Polona*. 1996;28(4):155–60. Available from:  
693 <https://pubmed.ncbi.nlm.nih.gov/9308339/>
- 694 42. Clavo B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G,  
695 Llontop P, Aguiar-Bujanda D, et al. Modulation of Oxidative Stress by Ozone  
696 Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity:  
697 Review and Prospects. *Antioxidants*. 2019;8(12):588. Available from:  
698 <https://www.mdpi.com/2076-3921/8/12/588>
- 699 43. Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear  
700 cells. *Toxicology in Vitro*. 2005;19(1):55–61.
- 701 44. Peralta C, Xaus C, Bartrons R, Leon OS, Gelpi E, Roselló-Catafau J. Effect of  
702 ozone treatment on reactive oxygen species and adenosine production during  
703 hepatic ischemia-reperfusion. *Free Radic Res*. 2000;33(5):595–605. Available  
704 from: <https://pubmed.ncbi.nlm.nih.gov/11200091/>
- 705 45. Bocci V, Valacchi G, Corradeschi F, Aldinucci C, Silvestri S, Paccaginini E, et  
706 al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen  
707 species (ROS) after exposure of human blood to ozone. *Journal of Biological*  
708 *Regulators & Homeostatic Agents*. 1998;12(3):67–75. Available from:  
709 <https://pubmed.ncbi.nlm.nih.gov/9795834/>



- 710 46. Re L. Ozone in Medicine: A Few Points of Reflections. *Frontiers in Physiology*.  
711 2022;13:103.
- 712 47. Tricarico G, Travagli V. The Relationship between Ozone and Human Blood in  
713 the Course of a Well-Controlled, Mild, and Transitory Oxidative Eustress.  
714 *Antioxidants* (Basel). 2021;10(12):1946–60. Available from:  
715 <https://pubmed.ncbi.nlm.nih.gov/34943049/>
- 716 48. Koca K, Yurttaş Y, Yildiz C, Çayci T, Uysal B, Korkmaz A. Effect of hyperbaric  
717 oxygen and ozone preconditioning on oxidative/nitrosative stress induced by  
718 tourniquet ischemia/reperfusion in rat skeletal muscle. *Acta Orthop Traumatol*  
719 *Turc.* 2010;44(6):476–83. Available from:  
720 <https://pubmed.ncbi.nlm.nih.gov/21358255/>
- 721 49. Ekici S, Doan Ekici AI, Öztürk G, Benli Aksungar F, Sinanolu O, Turan G, et al.  
722 Comparison of melatonin and ozone in the prevention of reperfusion injury  
723 following unilateral testicular torsion in rats. *Urology*. 2012;80(4):899–906.  
724 Available from: <https://pubmed.ncbi.nlm.nih.gov/22950989/>
- 725 50. Merin O, Attias E, Elstein D, Schwalb H, Bitran D, Zimran A, et al. Ozone  
726 administration reduces reperfusion injury in an isolated rat heart model. *J Card*  
727 *Surg.* 2007;22(4):339–42. Available from:  
728 <https://pubmed.ncbi.nlm.nih.gov/17661780/>
- 729 51. Kurtoglu T, Durmaz S, Akgullu C, Gungor H, Eryilmaz U, Meteoglu I, et al.  
730 Ozone preconditioning attenuates contrast-induced nephropathy in rats.  
731 *Journal of Surgical Research*. 2015;195(2):604–11. Available from:  
732 <https://www.sciencedirect.com/science/article/pii/S0022480415000700>
- 733 52. Wang L, Chen H, Liu XH, Chen ZY, Weng XD, Qiu T, et al. The protective  
734 effect of ozone oxidative preconditioning against hypoxia/reoxygenation injury  
735 in rat kidney cells. <http://dx.doi.org/10.3109/0886022X2014950934>.  
736 2014;36(9):1449–54. Available from:  
737 <https://www.tandfonline.com/doi/abs/10.3109/0886022X.2014.950934>
- 738 53. Meng W, Xu Y, Li D, Zhu E, Deng L, Liu Z, et al. Ozone protects rat heart  
739 against ischemia-reperfusion injury: A role for oxidative preconditioning in  
740 attenuating mitochondrial injury. *Biomedicine & Pharmacotherapy*.  
741 2017;88:1090–7. Available from:  
742 <https://www.sciencedirect.com/science/article/abs/pii/S0753332216320030>


- 743 54. Orlandin JR, Machado LC, Ambrósio CE, Travagli V. Ozone and its derivatives  
744 in veterinary medicine: A careful appraisal. Veterinary and Animal Science.  
745 2021;13:100191.  
746






A

## SH-SY5Y MTT




B

## AMSC MTT




C



## AMSC SOD




D

## AMSC CAT




**A****B**


A



B




C







A




B




C



A



B



C

